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ABSTRACT 
 
Objective 
To determine the influence of the genotype and the level of expression of different 
enzymes involved in folate metabolism on the response to and toxicity of high-dose 
methotrexate treatment in pediatric osteosarcomas. 
 
Study design 
DHFR and Reduced folate carrier 1 (RFC1) semiquantitative expression was analyzed 
in 34 primary and metastatic osteosarcoma tissues by real-time polymerase chain 
reaction. The following polymorphisms were also analyzed in peripheral blood from 96 
children with osteosarcoma and 110 control subjects: C677T, A1298C (MTHFR), 
G80A (RFC1), A2756G (MTR), C1420T (SHMT), the 28bp-repeat polymorphism, and 
1494del6 of the TYMS gene. Treatment toxicity was scored after each cycle according 
to criteria from the World Health Organization. 
 
Results 
DHFR and RFC1 expression was lower in initial osteosarcoma biopsy specimens than 
in metastases (P = .024 and P = .041, respectively). RFC1 expression was moderately 
decreased in samples with poor histologic response to preoperative treatment (P = .053). 
Patients with osteosarcoma with G3/G4 hematologic toxicity were more frequently TT 
than CT/CC for C677T/MTHFR (P = .023) and GG for A2756G/MTR (P = .048 and P 
= .057 for gastrointestinal and hematologic toxicity, respectively). 
 
Conclusions 
The role of C677T/MTHFR and A2756G/MTR on chemotherapy-induced toxicity 
should be further investigated in pediatric osteosarcomas receiving high-dose 
methotrexate. Altered expression of DHFR and RFC1 is a feasible mechanism by which 
osteosarcoma cells become resistant to methotrexate.  
ABBREVIATIONS 
 
DHFR Dihydrofolate reductase 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
mRNA 
HD-MTX High-dose methotrexate 
MTHFR 5,10-Methylenetetrahydrofolate reductase 
MTR Methionine synthase 
MTX Methotrexate 
OR Odds ratios 
RFC1 Reduced folate carrier I 
SHMT Serine hydroxymethyltransferase 
TYMS Thymidylate synthetase 
 
 
 
 
INTRODUCTION 
 
Osteosarcoma is the most common primary bone tumor in the first 3 decades of life and 
accounts for about 4% of all childhood tumors in Spain.1 Treatment for osteosarcoma 
includes surgery and preoperative and postoperative chemotherapy; for patients with 
nonmetastatic disease, the overall disease-free survival rate is about 65% to 70%.2 
Although the disease-free survival rate has improved dramatically with the advent of 
chemotherapy, only 50% to 60% of tumors are chemosensitive.3 
 
High-dose methotrexate (HD-MTX) is one of the main drugs used for osteosarcoma. 
MTX is a potent inhibitor of dihydrofolate reductase (DHFR), which converts 
dihydrofolate to the active tetrahydrofolate (Figure). In addition, the metabolized 
polyglutamated forms of MTX inhibit several other enzymes involved in the folate 
cycle, such as thymidylate synthetase (TYMS), and the combined effect is the inhibition 
of RNA and DNA synthesis.4
 
Functional polymorphisms in genes involved in the folate pathway are highly prevalent 
in the Caucasian population.5 In relation to cancer, the following variant genes have 
been analyzed in a wide variety of adult and pediatric tumors: the C677T and A1298C 
polymorphisms of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, which 
are associated with reduced enzyme activity in vitro6; a 28 bp tandem-repeat with a 
G>C substitution at the twelfth nucleotide in the second repeat of the 3R allele and 
1494del6 polymorphisms in the TYMS gene7,8; the A2756G missense mutation  
(D919G) in the methionine synthase (MTR) gene9; and the C1420T polymorphism in 
the hydroxymethyltransferase (SHMT) gene.10
 
The hypothesis is emerging that somatic differences in the genes encoding the enzymes 
involved in folate metabolism might not only influence toxicity but also response to 
folate-based chemotherapy. The scarce data available indicate that the intrinsic 
resistance of pediatric osteosarcoma to MTX may be mediated by an impaired transport 
of the drug because of decreased expression of reduced folate carrier (RFC1) or the 
increased expression of DHFR detected in tumor samples, and that factors regulating 
the cell cycle, such as RB1 and E2F, may influence this effect.11-13 In addition, reduced 
levels of RFC1 in these tumors can be attributed to either decreased gene expression or 
presence of gene polymorphisms that could affect the protein function. An example of 
the latter is G80A, which could affect plasma folate and MTX concentrations.14 
 
We hypothesized that, first, differences in the expression of folate enzymes (DHFR and 
RFC) in osteosarcoma tissues might be predictors of the response to MTX chemo-
therapy and thus, potentially, of survival; and second, that germline variations in folate 
pathway enzymes such as RFC, MTHFR, TYMS, SHMT, and MTR might affect the 
response to MTX chemotherapy or its toxicity. To test these hypotheses, we determined 
the genotype in 96 cases of pediatric osteosarcoma treated with HD-MTX and analyzed 
the level of expression of different enzymes involved in folate metabolism (Figure) in a 
subset (n = 34) of these patients for whom tumor tissues were available. 
 
 
 
METHODS 
 
Patients and Samples 
 
We analyzed the genomic DNA from peripheral blood of 96 children and adolescents 
with osteosarcoma (Table I). For a subset of these 96, we had frozen tumor tissue: 14 
biopsy specimens (from 14 patients) taken before chemotherapy and 20 metastases 
(from 17 patients). We analyzed the DNA from these frozen samples and from 15 
samples of normal bone. For comparative purposes, 110 blood samples were obtained 
from adults without previous history of bone tumor who attended the Department of 
Orthopaedic Surgery of our center. Control subjects were approximately matched with 
patients in terms of the numbers of males and females but were all taken from adults to 
rule out development of bone tumors in late infancy/early adulthood. None of the cases 
or control subjects had clinical indications of congenital folate metabolism syndromes. 
 
All the patients were treated and followed up at the Oncology Unit of the Department of 
Pediatrics of the University Clinic in Pamplona, Spain. In general, patients were treated 
before surgery with intravenous Adriamycin (doxorubicin, 3 courses at 25 to 30 
mg/m2/d for 3 days), intravenous methotrexate (4 courses of up to 14 g/m2/d for 1 day), 
and intraarterial cisplatin (3 courses at 35 mg/m2/d for 3 days) and, after surgery, the 
adjuvant chemotherapy included methotrexate (10 g/m2/d for 1 day) and alternate cycles 
of intravenous cisplatin/Adriamycin or intravenous actinomycin D (0.45 mg/m2/d for 3 
days), cyclophosfamide (500 mg/m2/d for 3 days), and vincristine (1.5 mg/m2/d for 1 
day) for up to 48 weeks of treatment. Approval was granted by the Ethics Committee of 
the University Clinic. In all cases, informed consent was obtained from the patient, 
parents, or both. Clinical data were collated and made anonymous within an unlinked 
SPSS 15.0 database (SPSS, Chicago, Illinois). Hematologic, gastrointestinal, and renal 
toxicities were scored according to the World Health Organization toxicity criteria.15 
 
 
Semiquantitative Real-time Polymerase Chain Reaction 
 
RNA was isolated from tissue samples by means of the TRIzol reagents (Gibco-BRL, 
Invitrogen, Invitrogen S.A., Barcelona, Spain). Random primers and Superscript 
polymerase and reactants (Invitrogen; Invitrogen S.A., Barcelona, Spain) were used to 
reverse-transcribe RNA (1 µg) to cDNA. Semiquantitative analysis of DHFR and RFC1 
mRNA expression in the tissue samples was carried out by real-time polymerase chain 
reaction (RT-PCR) with the ABI PRISM 7300 Sequence Detector and the software 
Sequence Detector version 1.4 (Perkin-Elmer/Applied Biosystems, Foster City, 
California). 
 
Semiquantitative DHFR and RFC1 mRNA levels were expressed as a percentage 
relative to that of glyceraldehyde-3-phosphate dehydrogenase mRNA (GAPDH), which 
was determined with TaqMan assays (Applied Biosystems). Relative levels of 
expression were determined by the Ct method, and every assay was performed in 
triplicate. To determine the cut-off point for altered RFC1 and DHFR expression in 
osteosarcoma samples, we assayed the expression in 15 normal bone samples obtained 
from the same patients at tumor resection. We considered expression to be normal if it 
was within 3 SD above or below the mean value of expression obtained for normal bone 
tissues. 
 
 
Genotyping of Folate Pathway Genes 
 
Peripheral blood samples from 96 children and adolescents with osteosarcoma and from 
110 healthy adults were different. Polymorphic variants C677T and A1298C (MTHFR), 
G80A (RFC1), and A2756G (MTR) were detected by real-time PCR using the 
genotyping assays of Applied Biosystems (Applied Biosystems). SHMT1 C1420T 
genotypes were identified by direct sequencing of PCR products. The 28 bp tandem-
repeat and 1494del6 polymorphisms in the TYMS gene were evaluated on high-
resolution polyacrylamide gels after PCR. 
 
 
Statistical Analysis 
 
The χ2 distribution was used to compare genotype frequencies between groups 
(cases/control subjects, toxicity groups, and responders/non-responders). Given the lack 
of consensus over the most appropriate strategy for correcting for multiple tests,16 we 
used uncorrected P values. These ideally need adjustment to compensate for multiple 
testing, but the Bonferroni correction tended to overcompensate be-cause the markers 
were not all independent. 
 
Calculation of odds ratios (OR) with a 95% confidence interval and calculations to 
evaluate Hardy-Weinberg equilibrium were done with the SHEsis platform.17 In the 
case-control study of osteosarcomas and healthy control subjects, the power of detection 
of a risk of 2.25 with a significance of 5% (2-tailed test), assuming the frequency of the 
polymorphic alleles present in our normal sample, ranged from 76.2% for TYMS-
2R/3R and RFC1-G80A, 71.3% for MTHFR-C677T and SHMT-C1420T, 65.5% for 
TYMS-1494del6 to 45.6% for MTHFR-A1298C; except for the A2756G marker of the 
MTR gene, for which a limited power of 15.3% was calculated. 
 
The distributions of DHFR and RFC1 expression were nonparametric, and therefore we 
used the Kruskal-Wallis test to make comparisons. Overall survival data and event-free 
survival data were compared by means of the log rank test (Mantel-Cox test). 
 
RESULTS 
 
Genotype Analysis 
 
The genotype frequencies of the polymorphisms analyzed (MTHFR: C677T and 
A1298C; TYMS: 1494del6 and 5'-UTR 28 bp polymorphisms; RFC1: G80A; MTR: 
A2756G; and SHMT: C1420T) were in Hardy-Weinberg equilibrium (data not shown). 
There were no substantial case-control differences in the distribution of genotypes for 
the folate pathway polymorphisms (Table II). 
 
 
Genotype, Toxicity, and Survival 
 
In our series of pediatric and adolescent osteosarcomas, none of the polymorphic 
variants of the folate pathway enzymes was significantly related to prognosis (survival, 
event-free survival, development of metastasis) or to the response to treatment (tumor 
necrosis induced by the neo-adjuvant chemotherapy). 
 
The toxicity induced by the antitumoral treatment was determined after every 
chemotherapy cycle and classified according to the guidelines of the World Health 
Organization. Of our patients, 70.2% suffered some kind of hematologic toxicity 
(aplasia, neutropenia, anemia, leukopenia) to a severe degree: grades G3/G4. In 
addition, 29.3% of the patients had gastrointestinal toxicity (increased alkaline 
phosphatase, bilirubin, or transaminases) and 42.6% had renal toxicity (creatinine, 
hematuria, proteinuria). Globally, neither the gastrointestinal (P = .436) nor the renal (P 
= .876) toxicities adversely affected survival rates. There was, however, a clear negative 
relationship between a severe grade of hematologic toxicity and survival (P = .024, log 
rank test). 
 
As other researchers have detected in various solid tumors, we found some evidence of 
a correlation between the MTHFR C677T allele and hematologic toxicity. The 
statistical significance of this relationship was borderline: patients with osteosarcoma in 
whom severe hematologic toxicity (G3 and G4) developed were more frequently TT 
than CT or CC (for TT vs CT vs CC; uncorrected P = .05; for TT vs CT+CC, OR [IC 
95%], 3.95 [1.14; 13.7], uncorrected P = .023). 
 
Additionally, the GG genotype of the A2756G polymorphism (MTR) was 
overrepresented in the group of patients who had severe gastrointestinal toxicity (G3 
and G4, uncorrected P = .048) and also tended to be more frequent in the group of 
patients with hematologic toxicity (uncorrected P = .057). We found no significant 
relationships between A1298C (MTHFR), SHMT, RFC1 or TYMS polymorphisms and 
hematologic, gastric, or renal toxicities. 
 
 
Expression Analysis 
 
We extracted mRNA from 15 normal bone tissue samples and analyzed the expression 
of DHFR and RFC1 by real-time PCR. As a reference, we used GAPDH, which was the 
constitutive gene used for normalization of gene expression. In this way we established 
the range of normal expression as the interval between 3 SD above and below the mean 
value of expression found in normal bone tissue. The expression of DHFR and RFC1 
was then analyzed in 34 samples (14 diagnostic biopsy specimens and 20 metastases) 
from children with bone tumors. Of the 14 biopsy samples, 13 had reduced RFC1 levels 
at the time of diagnosis (Table III). In terms of relative expression, the median level of 
expression was significantly lower in initial biopsy specimens than in metastatic tissues 
both for DHFR (P = .041, Kruskal-Wallis test) and RFC1 (P = .024, Kruskal-Wallis 
test). 
  
Of the samples with a poor histologic response to preoperative treatment, 90% had 
decreased RFC1 expression levels. In contrast, 60% of the samples with a good 
histologic response had reduced RFC1 levels (P = .053, χ2 test). We detected no 
evidence of a relationship between DHFR expression and response to treatment           
(P = .234, χ2 test). 
 
 
DISCUSSION 
 
We identified the polymorphisms in the TYMS, MTHFR, RFC1, MTR, and SHMT 
genes in 96 children with osteosarcoma and 110 healthy control subjects and measured 
the expression of RFC1 and DHFR in 34 osteosarcoma tissue samples and 15 normal 
bones. Our goal was to determine how genetic variation in the folate pathway affects 
MTX toxicity and response in patients with osteosarcoma. 
 
There is minimal definite information regarding the putative association between 
polymorphisms in the TYMS, MTHFR, RFC1, MTR, and SHMT genes and treatment 
outcome or MTX toxicity in osteosarcoma. With regard to an association between 
genotype and toxicity induced by the antitumoral treatment in our series of pediatric 
osteosarcomas, we detected a moderate but statistically significant relationship between 
the MTHFR 677TT genotype and severe degree (grades G3 and G4) of hematologic 
toxicity (TT vs CT+CC, uncorrected P = .023). This finding is not unexpected; the same 
relationship has been found with other solid tumors,18 and according to a recent review 
article, most publications report that patients with lower MTHFR activity (MTHFR 
677TT individuals) are subject to greater MTX-associated toxicity.4
 
In addition, we found that the GG genotype of the A2756G polymorphism (MTR) was 
moderately overrepresented in the group of patients with severe gastrointestinal toxicity 
(uncorrected P = .048). The same genotype also tended to be more frequent in the group 
of patients with hematologic toxicity (uncorrected P = .057). The association of this 
polymorphism with MTX-induced toxicity has hardly been investigated, although there 
are a few reports concerning patients with rheumatoid arthritis treated with low-dose 
MTX. In patients with rheumatoid arthritis, some authors detected an increased 
incidence of MTX-induced accelerated nodulosis associated with the 2756GG 
genotype,19 others did not detect an increased frequency of adverse effects associated 
with the A2756G genotype.20 
 
In view of the number and range of discrete toxic effects observed in our patients with 
osteosarcoma, it would seem unlikely that the toxicity induced by the osteosarcoma 
treatment administered can be attributed to a single drug, such as MTX, even if 
administered at very high doses. Neither should one expect to explain everything with a 
single nucleotide polymorphism. Rather, we should look to attribute the varied toxicity 
to polymorphism in general in the metabolism, transport, and detoxification of MTX, 
cisplatin, and Adriamycin. 
 
MTX resistance can occur by one or more complex mechanisms involving impaired 
transport into the target cell by RFC1; increase of DHFR, as a result of increased 
transcription or DNA amplification; and decreased intracellular retention caused by 
decreased polyglutamylation.21 In osteosarcoma, where high doses of MTX are required 
to achieve a good histologic response, all of the above mechanisms could be involved in 
the intrinsic resistance to MTX. 
 
In this series of pediatric osteosarcoma, the vast majority of cases showed decreased 
RFC1 expression. Impaired transport of MTX by RFC1 into cancer cells therefore is the 
most feasible mechanism by which osteosarcoma cells become resistant to low-dose 
MTX. This mechanism has been proposed previously by Guo et al,13 who, as we have 
reported for our patients, found that a poor response to preoperative chemotherapy was 
significantly related to decreased expression of RFC1. Similarly, our results support 
those of Ifergan et al,22 who proposed that the determination of RFC1 levels in samples 
at the time of diagnosis might be a useful predictor of patient chemosensitivity. As 
already mentioned, however, MTX resistance can occur as a result of several 
mechanisms. Furthermore, the observed histologic response is not due to MTX alone 
but rather to the combined effect of MTX, Adriamycin, and intraarterial cisplatin; 
various studies have demonstrated the role of genetic variability in the response to the 
latter 2 drugs in patients with osteosarcoma.23,24 
 
The increase of DHFR levels in metastatic tissues com-pared with primary tumors is in 
good agreement with the findings of other authors,13,21 who have postulated that this 
may be a mechanism of acquired MTX resistance or a difference between primary and 
metastatic tumors. In 5 resection specimens that we studied (data not shown), RFC1 and 
DHFR expression was more similar to that of metastatic tissues than to that of biopsy 
specimens. Although the small sample size cannot justify definitive conclusions, these 
observations support the hypothesis that an increase in RFC1 and DHFR expression 
reflects an acquired mechanism of the tumor cell, partially as a result of treatment rather 
than being intrinsic to the disease stage. 
 
Unfortunately, we did not evaluate folate and homocysteine levels, which are an 
important part of the phenotypic effect of the polymorphisms examined. It would also 
be interesting to have specific data concerning MTX kinetics in our patients with 
osteosarcoma. On the other hand, one of the strengths of the study is that, despite the 
relatively small number of patients, there is extensive and complete clinical and toxicity 
data from diagnosis to disease outcome. 
 
In conclusion, in this series of pediatric osteosarcomas receiving HD-MTX, the 
polymorphisms MTHFR/C677T and MTR/A2756G were associated with increased 
chemotherapy-induced toxicity. The reduced levels of RFC1 expression detected in 
osteosarcoma biopsies suggests that a feasible mechanism by which osteosarcoma cells 
become resistant to low-dose MTX involves impaired transport of MTX by RFC1 into 
the cancer cell. Further studies with series of patients with osteosarcoma for whom the 
folate and homocysteine levels are determined or for whom there is adequate 
assessment of diet and dietary supplements will be critical for drawing definite 
conclusions. 
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Table 1. Clinicopathologic features of 96 patients             
with osteosarcoma 
 Mean (SD) or Frequency (%) 
Sex  
Male 41 (42.7%) 
Female 55 (57.3%) 
Histologic study  
Osteoblastic 52 (54.2%) 
Chondroblastic 16 (16.7%) 
Other 28 (29.2%) 
Location  
Extremity 91 (94.8%) 
Central 5 (5.2%) 
Metastasis  
No 49 (51.3%) 
At diagnosis 18 (18.6%) 
At follow-up 29 (30.1%) 
Response to treatment  
Good (≥90%) 48 (50%) 
Poor (<90%) 39 (40.6%) 
Not available 9 (9.4%) 
Age at diagnosis (years) 14.5 (4.74) 
Overall survival* 112.8 (4; 262) 
Event-free survival† 102.7 (0; 262) 
*Overall survival: time in months from diagnosis until death or 
until the study’s end-date (ie, length of follow-up) expressed as 
median (range). 
†Event-free survival: time in months from diagnosis until 
clinical remission or first event (death, metastasis or relapse) 
expressed as median (range). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Genotype frequencies, odds ratios, and associated probabilities for polymorphisms       
in TYMS, MTFHR, SHMT, MTR, and RFC1 genes in the blood samples of children            
with osteosarcoma and in control subjects 
 Control subjects(n = 110) 
Osteosarcomas
(n = 96) OR (CI) P value 
TYMS 3R-2R     
3R/3R 26 (23.6%) 30 (31.3%) 1.26 (0.57; 2.8) .56 
3R/2R 62 (56.4%) 46 (47.9%) 0.83 (0.41; 1.7) .609 
2R/2R 22 (20%) 20 (20.8%) 1 Referent* 
3R/3R vs 3R72R+2R/2R   1.45 (0.8; 2.6) .084 
TYMS, 1494del6     
ins/ins 49 (44.5%) 46 (47.9%) 1 Referent* 
ins/del 44 (40%) 35 (36.5%) 0.84 (0.45; 1.5) .576 
del/del 17 (15.5%) 15 (15.6%) 0.93 (0.41; 2.1) .873 
MTHFR, C677T     
CC 35 (31.8%) 35 (36.5%) 1 Referent* 
CT 54 (49.1%) 47 (49%) 0.87 (0.47; 1.6) .656 
TT 21 (19.1%) 14 (14.6%) 0.67 (0.3; 1.5) .333 
MTHFR, A1298C     
AA 66 (60%) 53 (55.2%) 1 Referent* 
AC 35 (31.8%) 36 (37.5%) 1.26 (0.7; 2.3) .44 
CC 9 (8.2%) 7 (7.3%) 1.1 (0.36; 3.1) .898 
SHMT, C1420T     
CC 49 (44.5%) 35 (36.4%) 1 Referent* 
CT 39 (35.4%) 40 (41.7%) 1.48 (0.8; 2.7) .21 
TT 21 (19.1%) 21 (21.9%) 1.48 (0.7; 3.1) .305 
RFC1, G80A     
GG 29 (26.4%) 29 (30.2%) 1 Referent* 
GA 55 (50%) 49 (51%) 0.9 (0.47; 1.7) .739 
AA 26 (23.6%) 18 (18.8%) 0.7 (0.32; 1.52) .453 
MTR, A2756G     
AA 78 (70.9%) 72 (75%) 1 Referent* 
AG 30 (27.3%) 23 (24%) 0.83 (0.44; 1.55) .556 
GG 2 (1.8%) 1 (1%) 0.56 (0.06; 5.45) .591 
CI, Confidence interval. 
*Genotype considered to be the reference group, with an OR=1. 
 
 
 
 
 
Table 3. Level of expression of DHFR and RFC1 in primary osteosarcoma tissues and metastases 
DHFR (P = .062) RFC1 (P = .1) 
Tissue type No. 
Low* Normal* High* Low* Normal* 
Biopsy 14 9 (64.3%) 4 (28.6%) 1 (7.1%) 13 (92.9%) 1 (7.1%) 
Metastases 20 6 (30%) 6 (30%) 8 (40%) 11 (68.8%) 5 (31.3%) 
*The ratio of expression of DHFR or RFC1 relative to GAPDH in the tumor tissue was within the 
interval of 3 SD above and below the mean of the normalized expression in normal bone tissue. Low: 
below the normal range. High: above the normal range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. Overview of folate metabolism and transport. The enzymes analyzed in this 
study are highlighted. 
 
 
 
 
